ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
bullish•Alibaba
•16 Jan 2020 14:57

2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
723 Views
Share
•14 Jan 2020 17:44

Jiumaojiu (九毛九) Trading - Off to a Great Start with 638x Oversubscription

Jiumaojiu (9922 HK) raised about US$283m at HK$6.60 per share, the top end of its IPO price range. We have previously covered the IPO...

Share
•09 Dec 2019 17:08

Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level

Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...

Logo
711 Views
Share
bullish•Alphamab Co Ltd
•08 Dec 2019 13:19

ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...

Share
•01 Dec 2019 11:18

ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...

Share
x